Patent US2097850A successfully refreshed from Google Patents.
US4755375A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and kit for the selective labeling of red blood cells in whole blood with TC-99M
Assignee: Brookhaven Science Associates LLC
•
Filing: 1986-04-17
•
Granted: 1988-07-05
•
Expires: 2006-04-17
Abstract
Abstract Disclosed herein are a method and kit for the preparation of 99m Tc labeled red blood cells using whole blood in a closed sterile system containing stannous tin in a form such that it will enter the red blood cells and be available therein for the reduction of technetium.
Inventors
- 👤 Suresh C. Srivastava
- 👤 John W. Babich
- 👤 Rita Straub
- 👤 Powell Richards
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:22
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1203; A61K2123/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
224 words
A method of labeling red blood cells with 99m Tc consisting essentially of: A. supplying a sample of whole blood, including plasma and the red blood cells to be labeled, to a container having therein under sterilized conditions a lyophilized stannous ion complex with a tin content of from 5-1000 μg together with a tin complex stabilizer and incubating the mixture for a sufficient time to permit some of the stannous ion complex to pass through the membranes of the red blood cells into the cells; b. subjecting the resulting suspension of red blood cells in plasma to the action of an oxidizing agent to convert substantially all of the stannous tin in the plasma to stannic tin; C. incubating the avove suspension with a chelating agent for both stannic and residual stannous tin in the plasma to form tin chelates; and D. incubating the resulting suspension with a source of 99m Tc pertechnetate ion, in a form in which the ion will pass through the cell membranes of the red blood cells into the red blood cells, for a sufficient period of time to permit the stannous ions within the red blood cells to reduce the technetium to a lower valence state in which it will not pass out of the cells through the cell membrane, thereby labeling the cells with 99m Tc.
Claim 2
Independent Claim
224 words
A method of labeling red blood cells with 99m Tc consisting essentially of: A. supplying a sample of whole blood, including plasma and the red blood cells to be labeled, to a container having therein under sterilized conditions a lyophilized stannous ion complex with a tin content of from 5-1000 μg together with a tin complex stabilizer and incubating the mixture for a sufficient time to permit some of the stannous ion complex to pass through the membranes of the red blood cells into the cells; b. subjecting the resulting suspension of red blood cells in plasma to the action of an oxidizing agent to convert substantially all of the stannous tin in the plasma to stannic tin; C. incubating the avove suspension with a chelating agent for both stannic and residual stannous tin in the plasma to form tin chelates; and D. incubating the resulting suspension with a source of 99m Tc pertechnetate ion, in a form in which the ion will pass through the cell membranes of the red blood cells into the red blood cells, for a sufficient period of time to permit the stannous ions within the red blood cells to reduce the technetium to a lower valence state in which it will not pass out of the cells through the cell membrane, thereby labeling the cells with 99m Tc.
Claim 3
Dependent Claim
21 words
A method as in claim 1 wherein the whole blood is treated with an anti-coagulant agent before it enters the container.
Claim 4
Dependent Claim
11 words
The method of claim 2 wherein the anti-coagulant agent is heparin.
Claim 5
Dependent Claim
31 words
A method as in claim 1 wherein said container also contains an anti-coagulant so that the whole blood is prevented from coagulating by the action of said anti-coagulant in the container.
Claim 6
Dependent Claim
51 words
A method as in claim 1 wherein the stannous ion is complexed with a complexing agent selected from the group consisting of alkali metal citrates, alkali metal glucoheptonates, alkaline earth metal citrates, alkaline earth metal glucoheptonates, alkali metal tartrates, alkali metal pyrophosphates, organic diphosphonates, ethylenediaminetetraacetic acid, dimercaptosuccinic acid and diethylenetriaminepentaacetic acid.
Claim 7
Dependent Claim
12 words
The method of claim 5 wherein the complexing agent is sodium citrate.
Claim 8
Dependent Claim
12 words
The method of claim 5 wherein the complexing agent is sodium glucoheptonate.
Claim 9
Dependent Claim
14 words
A method of claim 1 wherein the tin complex stabilizer is a reducing sugar.
Claim 10
Dependent Claim
11 words
The method of claim 8 wherein the reducing sugar is dextrose.
Claim 11
Dependent Claim
14 words
A method of claim 1 wherein the oxidizing agent is an alkali metal hypochlorite.
Claim 12
Dependent Claim
27 words
A method of claim 1 wherein the chelating agent is selected from the group consisting of disodium ethylenediaminetetraacetic acid, calcium disodium ethylenediaminetetraacetic acid, and acid citrate dextrose.
Claim 13
Dependent Claim
19 words
A method of claim 1 wherein the source of the 99m Tc pertechnetate ion is an alkali metal pertechnetate.
Claim 14
Dependent Claim
70 words
The method of claim 1 wherein the complexing agent is selected from the group consisting of sodium citrate and sodium glucophetonate, the tin complex stabilizer is dextrose, the oxidizing agent is an alkali metal hypochlorite, the chelating agent is selected from the group consisting of disodium ethylenediaminetetraacetic acid, calcium disodium ethylenediaminetetraacetic acid, and acid citrate dextrose, and the source of the 99m Tc pertechnetate ion is an alkali metal pertechnetate.
Claim 15
Dependent Claim
24 words
A method as in claim 13 wherein the oxidizing agent is sodium hypochlorite and the source of 99m Tc pertechnetate ion is sodium pertechnetate.
Claim 16
Dependent Claim
25 words
A method as in claim 1 wherein the incubation of Step D is conducted at an elevated temperature to damage the labeled red blood cells.
Claim 17
Dependent Claim
25 words
A method as in claim 13 wherein the incubation of Step D is conducted at an elevated temperature to damage the labeled red blood cells.
References Cited (Backward Citations)
US3725295A
Cited
US3991173A
Cited
US3988429A
Cited
US4097238A
Cited
US4300569A
Cited
US4313928A
Cited
US4342740A
Cited
US4372294A
Cited
US4443426A
Cited
US4692324A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-07-05 | 1992-01-04 | 1992-07-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-07-05 | 1996-01-04 | 1996-07-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-07-05 | 2000-01-04 | 2000-07-05 | $7700.00 | Window Closed / Lapsed |